Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease Janssen Research & Development LLC Ongoing Guselkumab 3 CNTO1959CRD3005 King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam), King Saud Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Ultragenyx Pharmaceutical Inc Ongoing UX007/triheptanoin, Medium-chain Triglycerides (MCT),Dextrose. Monosaccharide. Blood Glucose-Elevating Agents. 3 UX007-CL30 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) AstraZeneca Ongoing Lenvatinib (Lenvima) + Durvalumab (Imfinzi) + Tremelimumab (Imjudo) 3 D910VC00001 King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh)
A non-interventional, multinational,observational study with isatuximabin patients with relapsed and/orrefractory multiple myeloma (RRMM) Sanofi Ongoing SARCLISA® ( isatuximab - irfc ) 4 OBS16577 Mouwasat Hospital (Dammam),King Faisal Specialist Hospital and Research Center (Jeddah),King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh)
International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia (Interfant-21) King Abdullah International Medical Research Center (KAIMRC) Ongoing BLINATUMOMAB 3 SCT22R/016/12 King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah)
An Open label, Single Center, prospective interventional, phase II clinical trial to evaluate the Efficacy and Safety of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine(BV-AVD) combination escalation in advanced stage classical Hodgkin lymphoma patients who did not achieve interim Positron Emission Tomography (PET2) negativity (defined as Deauville score 3 or less) after 2 cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia Rejected BRENTUXIMAB VEDOTIN, DACARBAZINE, VINBLASTINE, DOXORUBICIN HYDROCHLORIDE 2 1 King Faisal Specialist Hospital and Research Center (Riyadh)
A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum Cristcot HCA LLC Ongoing Hydrocortisone Acetate 90 mg 3 CHS1221 King Abdulaziz Medical City NG (Jeddah),King Abdulaziz University Hospital (Jeddah),King Fahad Medical City (Riyadh)
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB Roche Rejected ATEZOLIZUMAB, SORAFENIB 3 MO42541 King Abdulaziz Medical City NG (Riyadh)
A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) AstraZeneca Ongoing Tozorakimab (MEDI3506) 3 D9185C00001 King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh)
REFINE: Regorafenib observational study in hepatocellular carcinoma Bayer Ongoing Stivarga (regorafenib) 4 19244 King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh),King Fahad Medical City (Riyadh),King Fahad Medical City (Riyadh),King Fahad Medical City (Riyadh), My Clinic (Jeddah)
View 121 - 130 From 804